Literature DB >> 7666091

Surgical treatment of spinal cord compression from epidural metastasis.

N Sundaresan1, V P Sachdev, J F Holland, F Moore, M Sung, P A Paciucci, L T Wu, K Kelligher, L Hough.   

Abstract

PURPOSE: A retrospective study of the results of neoplastic cord compression was undertaken to determine the effectiveness of surgical treatment and to assess quality of life in patients undergoing extensive procedures with potential morbidity. PATIENTS AND METHODS: Over a 5-year period (1989 to 1993), a total of 110 patients underwent surgery. Fifty-five patients (50%) had undergone prior treatment, including 47 (43%) who had failed to respond to prior irradiation (RT). Before surgery, 48 patients (44%) were nonambulatory, with severe paresis being present in 20. Surgery included staged anterior-posterior resections in 53 patients (48%), anterior resections in 33 (30%), and posterior resection in six (5%), all of whom required spinal instrumentation for reconstruction; only 18 patients underwent resection without instrumentation.
RESULTS: Postoperatively, 90 patients (82%) were improved, both in terms of pain relief and ambulatory status. Fifty-three patients (48%) experienced postoperative complications, related statistically to the following three factors: age over 65 years, prior treatment, and presence of paraparesis. The overall median survival duration was 16 months, with 46% alive at 2 years. Apart from primary tumor, the presence of preoperative paraparesis had the most significant impact on survival.
CONCLUSION: Our data suggest that the effective surgical treatment of neoplastic compression requires anterior-posterior resection in most patients to achieve the goal of total tumor resection, with the majority requiring instrumentation. Long-term survival is feasible in a subset of patients with this aggressive surgical approach.

Entities:  

Mesh:

Year:  1995        PMID: 7666091     DOI: 10.1200/JCO.1995.13.9.2330

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

Review 1.  Malignant spinal cord compression.

Authors:  Madhuri Yalamanchili; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2003-12

Review 2.  Emergency Neurologic Life Support: Spinal Cord Compression.

Authors:  Kristine H O'Phalen; E Bradshaw Bunney; John W Kuluz
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

Review 3.  Recent advances: neurosurgery.

Authors:  M Powell
Journal:  BMJ       Date:  1999-01-02

Review 4.  Rehabilitation and treatment of spinal cord tumors.

Authors:  Vishwa S Raj; Latanya Lofton
Journal:  J Spinal Cord Med       Date:  2013-01       Impact factor: 1.985

Review 5.  Emergency neurological life support: spinal cord compression (SCC).

Authors:  Kristine H O'Phelan; E Bradshaw Bunney; Scott D Weingart; Wade S Smith
Journal:  Neurocrit Care       Date:  2012-09       Impact factor: 3.210

6.  Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life.

Authors:  L Alvarez; A Pérez-Higueras; D Quiñones; E Calvo; R E Rossi
Journal:  Eur Spine J       Date:  2003-03-22       Impact factor: 3.134

7.  Emergency Neurologic Life Support: Spinal Cord Compression.

Authors:  Kristine H O'Phelan
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 8.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

9.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

10.  Neurological complications of neuroblastic tumors: experience of a single center.

Authors:  G Burca Aydin; M Tezer Kutluk; Munevver Buyukpamukcu; Canan Akyuz; Bilgehan Yalcin; Ali Varan
Journal:  Childs Nerv Syst       Date:  2009-08-28       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.